Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

NCT05108051 | Completed Phase 1

• 1 other identifier: ZSP1273-20-05
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.

Conditions

Drug-drug Interaction

Outcome Measures

Primary Outcomes (6)

• Plasma pharmacokinetics

  Tmax

  pre-dose and up to 72hours post-dose

• Plasma pharmacokinetics

  t1/2

  pre-dose and up to 72hours post-dose

• Plasma pharmacokinetics

  Cmax

  pre-dose and up to 72hours post-dose

• Plasma pharmacokinetics

  AUC0-∞

  pre-dose and up to 72hours post-dose

• Plasma pharmacokinetics

  CL/F

  pre-dose and up to 72hours post-dose

• Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)

  TEAEs will be summarized displaying the number of TEAEs along with the number and percentage of participants with at least one TEAE according to: Number of AEs, Severity and relation to study drug.

  up to 37days

Study Arms (3)

sequence 1

EXPERIMENTAL

Period 1: study of ZSP1273's pharmacokinetics at steady state； Period 2: study of Oseltamivir's pharmacokineticsat at steady state； Period 3: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state.

Drug: ZSP1273; Drug: Oseltamivir

sequence 2

EXPERIMENTAL

Period 1: study of Oseltamivir's pharmacokineticsat at steady state; Period 2: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 3: study of ZSP1273's pharmacokinetics at steady state.

Drug: ZSP1273; Drug: Oseltamivir

sequence 3

EXPERIMENTAL

Period 1: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 2: study of ZSP1273's pharmacokinetics at steady state; Period 3: study of Oseltamivir's pharmacokineticsat at steady state.

Drug: ZSP1273; Drug: Oseltamivir

Interventions

ZSP1273 DRUG

ZSP1273 tablets 600mg administered orally once daily

sequence 1; sequence 2; sequence 3

Oseltamivir DRUG

Oseltamivir 75mg administered orally twice daily

sequence 1; sequence 2; sequence 3

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Males and female subjects between 18-45 years (Both inclusive);
• Body weight is no less than 50kg in males and no less than 45kg in females.Body mass index (BMI) 18\~26 kg/m2 (Both inclusive); BMI is determined by the following equation: BMI = weight/height2 (kg/m2);
• Subjects (including partners) are willing to voluntarily use effective contraception from screening to 3 months after the last study drug administration.

You may not qualify if:

• Known history of allergic constitution (multiple drugs especially with ZSP1273 or oseltamivir and its preparation of the main ingredient allergy, food allergy);
• Subjects who donated blood or bleeding profusely(\> 450 mL)in the 3 months preceding study screening;
• History or presence of any disease or condition known to increase the risk of bleeding, eg.hemorrhoids, acute gastritis or gastric and duodenal ulcer, etc;
• Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening;
• Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of drug metabolic enzymes ，is intended to be taken in combination 28 days prior to screening or during the study period；
• Participated in another clinical research study or received any investigational products within 3 months prior to dosing;
• Presence of clinically significant abnormalities in ECG , QTcB\>450ms in males,or QTcB\>470ms in females;
• Any of the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases) that are clinically significant in clinical laboratory examination or other clinical findings within 6 months prior to screening;
• Breast-feeding women or those with positive pregnancy test results;
• Subjects who should not be included in the study in the opinion of the Investigator.

Sponsors & Collaborators

• Guangdong Raynovent Biotech Co., Ltd: lead

Study Sites (1)

Guangdong Provincial Hospital of Chinese Medicine

Guangzhou, Guangdong, 510000, China

Location

Related Publications (1)

• Pang Y, Li H, Chen X, Cao Y, Jiang H, Huang J, Liu Y. A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects. Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0172924. doi: 10.1128/aac.01729-24. Epub 2025 Feb 24.

  PMID: 39992105 DERIVED

MeSH Terms

Interventions

ZSP1273; Oseltamivir

Intervention Hierarchy (Ancestors)

Acetamides; Amides; Organic Chemicals; Cyclohexenes; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2021
• First Posted: November 4, 2021
• Study Start: November 19, 2020
• Primary Completion: March 17, 2021
• Study Completion: March 17, 2021
• Last Updated: November 4, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)